GCG and metabolic dysfunction-associated steatohepatitis: Obesity is a major risk factor for NASH, and metabolic interventions such as bariatric surgery (BS) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been explored for their impact on liver‐related outcomes.